RhumbLine Advisers
ACRS icon

RhumbLine Advisers’s Aclaris Therapeutics ACRS Stock Holding History

RhumbLine Advisers’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Buy
75,401
+3,597
+5% +$12.1K ﹤0.01% 2935
2025
Q4 		$216K Sell
71,804
-19,432
-21% -$49.1K ﹤0.01% 3147
2025
Q3 		$173K Buy
91,236
+6,271
+7% +$10.9K ﹤0.01% 3297
2025
Q2 		$121K Buy
+84,965
New +$115K ﹤0.01% 3465
2024
Q3 		– Sell
-42,005
Closed -$46.2K – 4195
2024
Q2 		$46.2K Sell
42,005
-55,215
-57% -$64.9K ﹤0.01% 3707
2024
Q1 		$121K Buy
97,220
+1,470
+2% +$1.75K ﹤0.01% 3384
2023
Q4 		$101K Sell
95,750
-6,684
-7% -$20.4K ﹤0.01% 3446
2023
Q3 		$702K Sell
102,434
-1,893
-2% -$16.2K ﹤0.01% 2403
2023
Q2 		$1.08M Buy
104,327
+16,571
+19% +$150K ﹤0.01% 2246
2023
Q1 		$710K Buy
87,756
+1,894
+2% +$24K ﹤0.01% 2281
2022
Q4 		$1.35M Buy
85,862
+2,370
+3% +$38.1K ﹤0.01% 1990
2022
Q3 		$1.31M Buy
83,492
+11,493
+16% +$181K ﹤0.01% 1997
2022
Q2 		$1M Buy
71,999
+16,805
+30% +$236K ﹤0.01% 2144
2022
Q1 		$952K Buy
55,194
+8,469
+18% +$116K ﹤0.01% 2150
2021
Q4 		$679K Buy
46,725
+1,424
+3% +$21.6K ﹤0.01% 2380
2021
Q3 		$815K Buy
45,301
+3,435
+8% +$55.1K ﹤0.01% 2326
2021
Q2 		$735K Buy
+41,866
New +$951K ﹤0.01% 2383
2020
Q2 		– Sell
-51,626
Closed -$54K – 3059
2020
Q1 		$54K Sell
51,626
-4,368
-8% -$5.95K ﹤0.01% 2853
2019
Q4 		$106K Buy
55,994
+1,935
+4% +$3.21K ﹤0.01% 2869
2019
Q3 		$58K Buy
54,059
+4,164
+8% +$5.91K ﹤0.01% 2917
2019
Q2 		$109K Buy
49,895
+3,933
+9% +$21.4K ﹤0.01% 2915
2019
Q1 		$275K Buy
45,962
+6,472
+16% +$42.9K ﹤0.01% 2589
2018
Q4 		$292K Buy
39,490
+13,269
+51% +$137K ﹤0.01% 2561
2018
Q3 		$381K Sell
26,221
-905
-3% -$15.5K ﹤0.01% 2389
2018
Q2 		$542K Buy
27,126
+4,943
+22% +$91.3K ﹤0.01% 2272
2018
Q1 		$389K Buy
22,183
+90
+0.4% +$1.91K ﹤0.01% 2320
2017
Q4 		$545K Sell
22,093
-1,955
-8% -$47.6K ﹤0.01% 2197
2017
Q3 		$621K Buy
24,048
+1,095
+5% +$29.3K ﹤0.01% 2209
2017
Q2 		$622K Buy
22,953
+11,266
+96% +$306K ﹤0.01% 2190
2017
Q1 		$349K Buy
11,687
+1,555
+15% +$44.8K ﹤0.01% 2429
2016
Q4 		$275K Buy
10,132
+1,940
+24% +$49.5K ﹤0.01% 2524
2016
Q3 		$210K Buy
+8,192
New +$174K ﹤0.01% 2654

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RhumbLine Advisers's ACRS Position: Q1 2026 in Review

RhumbLine Advisers increased its Aclaris Therapeutics (ACRS) stake by 5% in Q1 2026, buying an estimated $12.1K and bringing the position to 75,401 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #2935.

RhumbLine Advisers first reported a position in ACRS in Q3 2016 and has held it in 32 quarters since. The position peaked at $1.35M in Q4 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • RhumbLine Advisers held 75,401 shares of Aclaris Therapeutics worth $283K as of Q1 2026.
  • RhumbLine Advisers bought 3,597 Aclaris Therapeutics shares in Q1 2026, an estimated $12.1K.
  • Aclaris Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2935 holding.
  • RhumbLine Advisers first reported a position in Aclaris Therapeutics in Q3 2016 and has held it in 32 quarters since.
  • RhumbLine Advisers's Aclaris Therapeutics position peaked at $1.35M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.